Compare XPL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | ICCC |
|---|---|---|
| Founded | 1984 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.1M | 64.0M |
| IPO Year | 2000 | 1995 |
| Metric | XPL | ICCC |
|---|---|---|
| Price | $0.89 | $8.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.20 | N/A |
| AVG Volume (30 Days) | ★ 177.9K | 23.1K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.86 | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.54 | $4.52 |
| 52 Week High | $0.98 | $8.23 |
| Indicator | XPL | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 73.21 |
| Support Level | $0.70 | $5.78 |
| Resistance Level | $0.98 | N/A |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 75.61 | 87.88 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.